Filing summary
Registrant mismatch: The supplied filing is Priveterra Acquisition Corp.’s Form 10-Q for the quarter ended September 30, 2022, not an AEON Biopharma, Inc. filing. The summary below reflects the filing text provided.
Business context and reporting period
Priveterra was a shell company formed to pursue a business combination and had not begun operations or generated operating revenue. The report covers the three and nine months ended September 30, 2022, with comparisons to the corresponding 2021 periods. Its IPO trust held approximately $277.2 million at quarter-end. The company had until February 11, 2023 to complete a business combination or face liquidation under its stated terms.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Operating revenue | $0 | $0 | $0 | $0 |
| Formation and operating costs | $488,099 | $450,892 | $1,304,376 | $1,050,199 |
| Net income | $1,642,459 | $5,658,942 | $6,282,956 | $7,952,957 |
| Operating cash flow | Not separately provided for quarter | Not separately provided for quarter | $(811,153) | $(1,332,155) |
2022 net income primarily reflected warrant fair-value gains and interest earned in the trust: $1.2 million and $1.2 million, respectively, in Q3; $6.4 million and $1.4 million, respectively, for the first nine months. The income statement labels the warrant line “unrealized loss” while reporting positive amounts; MD&A describes them as gains. Net income per share was $0.05 for Q3 2022 and $0.18 for the nine-month period, versus $0.16 and $0.26 in 2021.
At September 30, cash outside the trust was $27,759; current assets were $166,171 and current liabilities were $1,348,027, including $254,238 of income tax payable. Management cited a $930,301 working-capital deficit excluding taxes payable funded from trust earnings. Trust investments were $277,156,370. Warrant liabilities were $961,413, down from $7,384,800 at December 31, 2021. No borrowings were outstanding; the $9.66 million deferred underwriters’ fee is payable only if a business combination closes. Stockholders’ deficit was $11.6 million.
Material changes, outlook and risks
- Net income declined year over year, while operating costs increased. Trust interest income increased substantially from 2021.
- Management stated that low operating cash, the working-capital deficit, and the approaching mandatory liquidation date raise substantial doubt about the company’s ability to continue as a going concern. It intends to complete a business combination before the deadline; the filing provides no assurance of completion.
- The filing identifies potential risks from COVID-19 and the war in Ukraine, with specific financial effects not determinable. A potential 1% federal excise tax on certain share repurchases after December 31, 2022 could reduce cash available for a transaction.
- No business or financial guidance was provided. The filing reported no legal proceedings and no off-balance-sheet arrangements.
- Management said disclosure controls were effective and described remediation of a previously identified material weakness in internal control; no material quarterly changes in internal control were reported.
Important facts for investors to verify
- Confirm the filing’s identity: it is for Priveterra Acquisition Corp., not AEON Biopharma, Inc.
- Review the inconsistent warrant fair-value line labeling (gain versus “unrealized loss”) and its effect on reported earnings.
- Verify the trust-account balances and available funds, the February 11, 2023 transaction deadline, and the consequences if no business combination closes.
- Assess liquidity outside the trust, the working-capital deficit, conditional deferred underwriting fee, and potential excise-tax impact.
- Review the status and effectiveness of remediation for the previously identified internal-control material weakness.